Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search

New Drug: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (EMERALD)

New Drug: Elacestrant for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (EMERALD)
Study:
  • International, multicenter, randomized, open-label, phase III
  • ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclin-dependent kinase 4/6 inhibitor, and ≤ 1 chemotherapy
  • Elacestrant (n=239) vs. SOC (n=238)
Efficacy:
  • 12 mos PFS in ITT: 22.3 vs. 9.4%, HR: 0.70, p=0.018
  • 12 mos PFS in ESR1 mutant pts: 26.8 vs. 8.2%, HR: 0.55, p=0.0005
  • 12 mos OS in ITT: 79.3 vs. 73.3%, HR: 0.75, p=0.082
  • 12 mos OS in ESR1 mutant pts: 82.6 vs. 73.6%, HR: 0.59, p=0.030
Safety:
  • Grade≥3 AEs: Nausea (2.5% vs.2.9%), back pain )2.5% vs. 0.6%), fatigue (1.5% vs. 0.8%)

J Clin Oncol 2022 40:28, 3246-3256

Bidard F-C et al. ¨Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial ¨

http://doi.org/10.1200/JCO.22.00338

Reviewed by Elvin CHALABİYEV, MD on FEB 24, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More